


CLAIMS

What is claimed is:


1. A stilbene compound comprising the following structure:



wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 may each be independently hydrogen, hydroxyl [OH], nitrooxy [ONO₂], methoxy [OCH₃], ethoxy [OCH₂CH₃], fluoride [F], phosphate, acetyl [OCOR₁₁], O-sulfate [the sulfate conjugate], or O-glucoronidate [the glucuronic (AKA glucuronic) acid conjugates], with the proviso that at least one of R1-R10 is nitrooxy; and

wherein OCOR₁₁ means




wherein R₁₁ can be C₁₋₁₈, aryl, heteroaryl, and optionally substituted derivatives thereof; and wherein X can be a single, double or triple bond.

2. A method for treating cardiovascular, cholesterol or lipid related disorders in a patient comprising administering to a patient in need of treatment a therapeutically effective amount of a compound according to claim 1.

3. A method for inducing expression of ApoA1 while providing anti-oxidant activity in a patient comprising administering to said patient the compound of claim 1.

4. A method for reducing serum cholesterol in a patient comprising administering to said patient the compound of claim 1.


5. A flavonoid compound comprising the following structure:



wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₂ and R₁₃ may each be independently hydrogen, hydroxyl [OH], nitrooxy [ONO₂], methoxy [OCH₃], ethoxy [OCH₂CH₃], fluoride [F], phosphate, acetyl [OCOR₁₁], O-sulfate [the sulfate conjugate], or O-glucuronide [the glucuronic (AKA glucuronic) acid conjugates], with the proviso that at least one of R₁-R₁₀ or R₁₂ or R₁₃ is nitrooxy;

OCOR₁₁ means



wherein R₁₁ can be C₁₋₁₈, aryl, heteroaryl, and optionally substituted derivatives thereof;

X can be O or CR₁₂;


Y can be CO [a ketone still maintaining the 6 atom ring structure] or CR₁₃; and Z can be a single or a double bond.

6. A method for treating cardiovascular, cholesterol or lipid related disorders in a patient comprising administering to a patient in need of treatment a therapeutically effective amount of a compound according to claim 5.

7. A method for inducing expression of ApoA1 while providing anti-oxidant activity in a patient comprising administering to said patient the compound of claim 5.

8. A method for reducing serum cholesterol in a patient comprising administering to said patient the compound of claim 5.


9. An isoflavonoid compound comprising the following structure:



wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₂ and R₁₃ may each be independently hydrogen, hydroxyl [OH], nitrooxy [ONO₂], methoxy [OCH₃], ethoxy [OCH₂CH₃], fluoride [F], phosphate, acetyl [the ester OCOR₁₁], O-sulfate [the sulfate conjugate], or O-glucuronidate [the glucuronic (AKA glucuronic) acid conjugates], with the proviso that at least one of R₁-R₁₀ or R₁₂ or R₁₃ is nitrooxy;

OCOR₁₁ means



wherein R₁₁ can be C₁₋₁₈, aryl, heteroaryl, and optionally substituted derivatives thereof;

X can be O or CR₁₂;


Y can be CO [a ketone still maintaining the 6 atom ring structure] or CR₁₃; and Z can be a single or a double bond.

10. A method for treating cardiovascular, cholesterol or lipid related disorders in a patient comprising administering to a patient in need of treatment a therapeutically effective amount of a compound according to claim 9.

11. A method for inducing expression of ApoA1 while providing anti-oxidant activity in a patient comprising administering to said patient the compound of claim 9.

5 12. A method for reducing serum cholesterol in a patient comprising administering to said patient the compound of claim 9.

13. A chalcone compound comprising the following structure:




wherein

R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R12 and R13 may each be independently hydrogen, hydroxyl [OH], nitrooxy [ONO.sub.2], methoxy [OCH.sub.3], ethoxy [OCH.sub.2CH.sub.3], fluoride [F], phosphate, acetyl [the ester OCOR11], O-sulfate [the sulfate conjugate], or O-glucuronide [the glucuronic (AKA glucuronic) acid conjugates], with the proviso that at least one of R1-R10 or R12 or R13 is nitrooxy;

15

OCOR11 means



wherein R11 can be C₁₋₁₈, aryl, heteroaryl, and optionally substituted derivatives thereof;

X can be a single or a double bond;

Y can be a single or a double bond; and

Z can be CO [a ketone] or CR13;

25 with the proviso that X and Y are not both double bonds, and if Z is CO then Y is not a double bond.


14. A method for treating cardiovascular, cholesterol or lipid related disorders in a patient comprising administering to a patient in need of treatment a therapeutically effective amount of a compound according to claim 13.

5

15. A method for inducing expression of ApoA1 while providing anti-oxidant activity in a patient comprising administering to said patient the compound of claim 13.

10 16. A method for reducing serum cholesterol in a patient comprising administering to said patient the compound of claim 13.

17. A polyphenol compound comprising the following structure:




15 wherein

R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉ and R₁₀ may each be independently hydrogen, hydroxyl [OH], nitrooxy [ONO.sub.2], methoxy [OCH.sub.3], ethoxy [OCH.sub.2CH.sub.3], fluoride [F], phosphate, acetyl [the ester OCOR₁₁], O-sulfate [the sulfate conjugate], or O-glucuronidate [the glucuronic (AKA glucuronic) acid conjugates], with the proviso that at least one of R₁-R₁₀ is nitrooxy;

20

OCOR₁₁ means



wherein R₁₁ can be C₁₋₁₈, aryl, heteroaryl, and optionally substituted derivatives thereof;

25 X can be C, S, (CO), SO, AKA ketone, (SO.sub.2)N, (CO)C, (CO)N, (CO)O, C-N [single bond], C=N [double bond], C-O, N-O, N-N [single bond], or N=N [double bond].

18. A method for treating cardiovascular, cholesterol or lipid related disorders in a patient comprising administering to a patient in need of treatment a therapeutically effective amount of a compound according to claim 17.

5 19. A method for inducing expression of ApoA1 while providing anti-oxidant activity in a patient comprising administering to said patient the compound of claim 17.

20. A method for reducing serum cholesterol in a patient comprising administering to said patient the compound of claim 17.

10